AstraZeneca PLC 28 July 2016 07:00 This announcement contains inside information. H1 2016 Results Financial Summary    H1 2016     Q2 2016    % change  % change    $m  CER1  Actual  $m  CER1  Actual Total   Revenue  11,718  (3)  (5)  5,603  (10)  (11) Product Sales  11,034  (2)  (5)  5,469  (5)  (6) Externalisation 684  (12)  (12)  134  (72)  (72) Revenue Reported   1,341  (24)  (28)  303  (64)  (67) Operating Profit Core   Operating 2,999 (14) (17) 1,406 (21) (22) Profit2 Reported   $0.51  (45)  (48)  $0.00  (99)  (100) Earnings Per Share (EPS) Core   EPS  $1.78  (20)  (22)  $0.83  (31) ·    Total Revenue down by 3% as expected, reflecting a 2% decline in Product Sales that was driven by patent expiries, in particular Crestor in the US. The phasing of Externalisation Revenue is towards H2 2016 ·    Reported and Core R&D costs increased by 6% and 9% respectively; Reported SG&A costs were stable, with Core SG&A costs declining by 5%, supporting full-year commitments ·    Reported EPS declined 45%, negatively impacted by restructuring charges related to the recently-announced cost reduction programme. Core EPS declined 20%, reflecting the phasing of Externalisation Revenue to the second half of the year ·    An unchanged first interim dividend per share of $0.90 ·    FY 2016 guidance unchanged Commercial Highlights The Growth Platforms grew by 7% in the half. Of the six platforms, the performance included: · Emerging Markets: +7%. Encouraging China growth of 11% · Diabetes: +18%. A good performance underpinned by the success of Farxiga · Respiratory: +1%. Strong Emerging Markets sales of Symbicort, pricing compression in the US and Europe · New Oncology: Sales of $251m reflected the successful ongoing launch of Tagrisso Click on, or paste the following link into your web browser, to view the associated PDF document. http://www.rns-pdf.londonstockexchange.com/rns/4585F_1-2016-7-27.pdf

Ads